Cue Biopharma (CUE) — Cash Flow-to-Debt Ratio
Cue Biopharma (CUE) has a Cash Flow-to-Debt Ratio of -0.49x as of September 2025, meaning its operating cash flow of $-9.02 Million could theoretically repay 0% of its total liabilities ($18.40 Million) in one year. Explore Cue Biopharma (CUE) cash conversion ratio to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cue Biopharma Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Cue Biopharma across 10 annual periods. Also explore Cue Biopharma assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Cue Biopharma (2015–2024)
Year-by-year debt coverage analysis for Cue Biopharma. For market capitalisation and broader financial context, see Cue Biopharma market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.47x | $-36.33 Million | $14.69 Million | ▼ -51.3% |
| 2023 | -1.63x | $-39.96 Million | $24.45 Million | ▼ -0.1% |
| 2022 | -1.63x | $-41.81 Million | $25.60 Million | ▲ +24.7% |
| 2021 | -2.17x | $-38.84 Million | $17.91 Million | ▼ -37.6% |
| 2020 | -1.58x | $-32.49 Million | $20.62 Million | ▲ +12.9% |
| 2019 | -1.81x | $-30.80 Million | $17.02 Million | ▲ +22.0% |
| 2018 | -2.32x | $-26.41 Million | $11.39 Million | ▼ -1.7% |
| 2017 | -2.28x | $-12.19 Million | $5.35 Million | ▲ +57.8% |
| 2016 | -5.41x | $-5.97 Million | $1.10 Million | ▼ -22.7% |
| 2015 | -4.40x | $-1.66 Million | $376.30K | — |